{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:14Z","timestamp":1767916814277,"version":"3.49.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.jgyn.2011.09.022","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T22:01:10Z","timestamp":1320789670000},"page":"858-874","source":"Crossref","is-referenced-by-count":20,"title":["Place des traitements m\u00e9dicaux\u00a0: indication, dur\u00e9e, efficacit\u00e9, chez la femme porteuse de fibromes ut\u00e9rins symptomatiques en p\u00e9riode d\u2019activit\u00e9 g\u00e9nitale"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"Koskas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Chabbert-buffet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Douvier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Huchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Derrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgyn.2011.09.022_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0950-3552(98)80060-6","article-title":"Clinical presentation of uterine fibroids","volume":"12","author":"Lumsden","year":"1998","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0010","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/humrep\/deh407","article-title":"Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study","volume":"19","author":"Marino","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0029-7844(02)02007-0","article-title":"Natural history of uterine polyps and leiomyomata","volume":"100","author":"DeWaay","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0015-0282(02)04539-9","article-title":"The ontario uterine fibroid embolization trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life","volume":"79","author":"Pron","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/aje\/153.1.20","article-title":"Risk factors for uterine fibroids among women undergoing tubal sterilization","volume":"153","author":"Chen","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0030","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S0368-2315(08)74770-7","article-title":"Epidemiology of menometrorrhagia","volume":"37","author":"Huchon","year":"2008","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0035","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1289\/ehp.00108s5779","article-title":"Pathology and pathophysiology of uterine smooth-muscle tumors","volume":"108","author":"Robboy","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1289\/ehp.00108s5835","article-title":"Clinical decision making regarding leiomyomata: what we need in the next millenium","volume":"108","author":"Haney","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0045","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.83.11.4092","article-title":"Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment","volume":"83","author":"Englund","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1071-5576(02)00253-8","article-title":"Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels","volume":"10","author":"Amant","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1289\/ehp.00108s5829","article-title":"Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro\/in vivo animal model for uterine fibroids","volume":"108","author":"Hunter","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/humrep\/12.4.815","article-title":"Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium","volume":"12","author":"Viville","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0065","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1289\/ehp.00108s5791","article-title":"Advances in uterine leiomyoma research: the progesterone hypothesis","volume":"108","author":"Rein","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0070","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.83.6.2192","article-title":"Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma","volume":"83","author":"Shimomura","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","article-title":"Uterine fibroids","volume":"357","author":"Stewart","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/j.1600-0412.2001.080006497.x","article-title":"Expression of basic fibroblast growth factor (bFGF), FGF receptor 1\u00a0and FGF receptor 2\u00a0in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment","volume":"80","author":"Wu","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.biochi.2005.07.014","article-title":"Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth","volume":"88","author":"Wolanska","year":"2006","journal-title":"Biochimie"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mob.2003.118","article-title":"Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1\u00a0in human myometrium and leiomyoma","volume":"188","author":"Arici","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1067\/mob.2003.140","article-title":"Increased expression of cyclin G1\u00a0in leiomyoma compared with normal myometrium","volume":"188","author":"Baek","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1933719107314063","article-title":"Loss of cyclin g1\u00a0expression in human uterine leiomyoma cells induces apoptosis","volume":"15","author":"Kwon","year":"2008","journal-title":"Reprod Sci"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0105","first-page":"158","article-title":"The effect of a new potent antifibrinolytic agent, tranexamic acid","volume":"13","author":"Kobayashi","year":"1966","journal-title":"J Jpn Obstet Gynecol Soc"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.313.7057.579","article-title":"Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid","volume":"313","author":"Bonnar","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1469-0705.1998.11040283.x","article-title":"Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid","volume":"11","author":"Lakhani","year":"1998","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/PAS.0b013e318032125e","article-title":"Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas","volume":"31","author":"Ip","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0002-9378(16)36139-7","article-title":"Response of fibromyomas to a progestin","volume":"82","author":"Mixson","year":"1961","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1471-0528.1996.tb09911.x","article-title":"Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case \u2013 control study","volume":"103","author":"Lumbiganon","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijgo.2003.09.010","article-title":"Depo medroxyprogesterone acetate (DMPA) therapy for uterine myomata prior to surgery","volume":"85","author":"Johnson","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/01443610400009543","article-title":"Medical management of uterine fibroids with medroxyprogesterone acetate (Depo-Provera): a pilot study","volume":"24","author":"Venkatachalam","year":"2004","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0140","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0039-128X(00)00174-4","article-title":"Progestins and cardiovascular risk markers","volume":"65","author":"Sitruk-Ware","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0301-2115(99)00168-2","article-title":"Leuprorelin depot 3.75mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial","volume":"89","author":"Verspyck","year":"2000","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0303-7207(02)00230-7","article-title":"Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells","volume":"196","author":"Hodges","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0155","first-page":"175","article-title":"Traitement m\u00e9dical des fibromes ut\u00e9rins par les progestatifs de synth\u00e8se du groupe norpr\u00e9gnane","volume":"40","author":"Rozenbaum","year":"1989","journal-title":"Gyn\u00e9cologie"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0160","first-page":"23","article-title":"Utilisation de la promegestone dans le traitement des fibromyomes compliqu\u00e9s de m\u00e9nom\u00e9trorragies. Bilan d\u2019une \u00e9tude multicentrique","volume":"40","author":"Audebert","year":"1989","journal-title":"Gyn\u00e9cologie"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0165","first-page":"153","article-title":"Traitement m\u00e9dical des fibromes ut\u00e9rins par un progestatif de synth\u00e8se du groupe norpr\u00e9gnane","volume":"17","author":"Rozenbaum","year":"1989","journal-title":"Contracept Fertil Sex"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0170","first-page":"1","article-title":"Traitement m\u00e9dical des fibromyomes ut\u00e9rins par le nom\u00e9gestrol ac\u00e9tate","volume":"69","author":"Amadio","year":"1991","journal-title":"Abstract Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0175","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1471-0528.2002.01225.x","article-title":"Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review","volume":"109","author":"Lethaby","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/humrep\/14.suppl_1.194","article-title":"Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues","volume":"14","author":"Ortmann","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/humrep\/11.suppl_3.3","article-title":"GnRH agonists and uterine leiomyomas","volume":"11","author":"Broekmans","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0190","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0306-5456(00)00020-6","article-title":"The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review","volume":"108","author":"Stewart","year":"2001","journal-title":"BJOG"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0301-2115(01)00555-3","article-title":"The effect on menstrual blood loss in women with uterine fibroids of a novel \u201cframeless\u201d intrauterine levonorgestrel-releasing drug delivery system: a pilot study","volume":"102","author":"Wildemeersch","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0010-7824(02)00522-X","article-title":"The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia","volume":"67","author":"Mercorio","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0205","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0015-0282(03)00175-4","article-title":"Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas","volume":"79","author":"Grigorieva","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/pgp.0b013e318134ebcc","article-title":"Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy","volume":"27","author":"Rizkalla","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0215","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000010199","article-title":"GnRH analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation","volume":"48","author":"Rintala","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0220","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09513599909167584","article-title":"Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata","volume":"13","author":"Nakayama","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0225","first-page":"222","article-title":"The effects of add-back therapy with tibolone on myoma uteri","volume":"29","author":"G\u00f6\u00e7men","year":"2002","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0015-0282(00)01676-9","article-title":"Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy","volume":"75","author":"Palomba","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2007.05.061","article-title":"Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas","volume":"90","author":"Palomba","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.steroids.2004.10.008","article-title":"Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern","volume":"70","author":"Di Lieto","year":"2005","journal-title":"Steroids"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0245","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0015-0282(16)59763-5","article-title":"A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri","volume":"49","author":"Friedman","year":"1988","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0250","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/oxfordjournals.humrep.a137643","article-title":"Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids","volume":"7","author":"West","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/humrep\/12.3.436","article-title":"Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability","volume":"12","author":"Caird","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0260","doi-asserted-by":"crossref","unstructured":"Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007:CD005287.","DOI":"10.1002\/14651858.CD005287.pub3"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0265","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/humrep\/17.12.3213","article-title":"Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial","volume":"17","author":"Palomba","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1472-6483(11)60220-4","article-title":"Will GnRH antagonists assist in the treatment of benign gynaecological diseases?","volume":"5","author":"Felberbaum","year":"2002","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1472-6483(10)61957-8","article-title":"Preoperative reduction of uterine fibroids in only 16\u00a0days by administration of a gonadotrophin-releasing hormone antagonist (cetrotide)","volume":"3","author":"Felberbaum","year":"2001","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0280","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/humrep\/12.9.2028","article-title":"Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix","volume":"12","author":"Gonzalez-Barcena","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejogrb.2006.07.018","article-title":"Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study","volume":"134","author":"Engel","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0290","doi-asserted-by":"crossref","unstructured":"Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Cochrane Database Syst Rev 2009:CD007692.","DOI":"10.1002\/14651858.CD007692.pub2"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0295","first-page":"463","article-title":"Short-term effects of danazol for uterine fibroids","volume":"19","author":"Zhang","year":"1998","journal-title":"Med Guangdong"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0300","first-page":"429","article-title":"A medical treatment for myomata uteri","volume":"39","author":"DeCherney","year":"1983","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0305","first-page":"105","article-title":"Treatment of uterine leiomyoma with danazol or mifepristone","volume":"3","author":"Peng","year":"2002","journal-title":"Pract Clin Med"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1447-0756.1995.tb00889.x","article-title":"Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin","volume":"21","author":"Ueki","year":"1995","journal-title":"J Obstet Gynaecol (Tokyo 1995)"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0315","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.fertnstert.2005.09.034","article-title":"Gestrinone versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation","volume":"85","author":"Triolo","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0320","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.fertnstert.2004.08.004","article-title":"Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply","volume":"82","author":"La Marca","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0301-2115(00)00468-1","article-title":"The role of tamoxifen in the treatment of symptomatic uterine leiomyomata \u2013 a pilot study","volume":"96","author":"Sadan","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0330","first-page":"677","article-title":"Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2\u00a0mutation treated by tamoxifen","volume":"31","author":"Doridot","year":"2002","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0335","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/jc.87.8.3603","article-title":"Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study","volume":"87","author":"Palomba","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.fertnstert.2003.06.009","article-title":"Raloxifene prevents the growth of uterine leiomyomas in premenopausal women","volume":"81","author":"Jirecek","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0345","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0015-0282(03)00261-9","article-title":"A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy","volume":"79","author":"Donnez","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0350","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-2007-1013603","article-title":"Effect of aminoglutethimide on androstenedione aromatase activity in human uterine leiomyoma","volume":"17","author":"Yamamoto","year":"1985","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0355","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0015-0282(02)04761-1","article-title":"Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a non-steroidal aromatase inhibitor","volume":"79","author":"Shozu","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0360","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.AOG.0000279151.20878.60","article-title":"The effect of anastrazole on symptomatic uterine leiomyomata","volume":"110","author":"Varelas","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0365","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2007.11.006","article-title":"Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients","volume":"91","author":"Hilario","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1472-6483(10)60246-5","article-title":"Treatment of symptomatic uterine leiomyoma with letrozole","volume":"17","author":"Gurates","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.fertnstert.2008.09.064","article-title":"A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status","volume":"93","author":"Parsanezhad","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0380","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/01.AOG.0000127622.63269.8b","article-title":"Systematic review of mifepristone for the treatment of uterine leiomyomata","volume":"103","author":"Steinauer","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0385","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","article-title":"Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone","volume":"109","author":"Feng","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0400","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0405","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0410","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/humupd\/dmi002","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"11","author":"Chabbert-Buffet","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0415","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3\u00a0months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0420","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0425","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0430","doi-asserted-by":"crossref","first-page":"767-72e1-2","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914\u00a0treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0435","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914\u00a0for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0440","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00003081-200106000-00019","article-title":"Identification of new therapies for leiomyomas: what in vitro studies can tell us","volume":"44","author":"Nowak","year":"2001","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0445","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(99)01648-7","article-title":"Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis","volume":"353","author":"Minakuchi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/jc.83.1.219","article-title":"Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production","volume":"83","author":"Lee","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0455","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.293.6543.359","article-title":"Risk factors for uterine fibroids: reduced risk associated with oral contraceptives","volume":"293","author":"Ross","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0460","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000291871","article-title":"Reduction in the size of a uterine leiomyoma following discontinuation of an estrogen-progestin contraceptive","volume":"43","author":"Barbieri","year":"1997","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0465","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0015-0282(98)00208-8","article-title":"A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata","volume":"70","author":"Marshall","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0470","first-page":"768","article-title":"Contraception, hormone replacement therapy and myomas","volume":"28","author":"Jamin","year":"1999","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0475","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1471-0528.1999.tb08409.x","article-title":"Use of oral contraceptives and uterine fibroids: results from a case-control study","volume":"106","author":"Chiaffarino","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0480","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0015-0282(16)58098-4","article-title":"The effects of hormone replacement therapy on uterine fibroids in postmenopausal women","volume":"65","author":"Sener","year":"1996","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0485","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0378-5122(96)00993-0","article-title":"Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women","volume":"23","author":"Ylostalo","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0490","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5122(00)00159-6","article-title":"Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT","volume":"37","author":"Polatti","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0495","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0029-7844(01)01598-8","article-title":"Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas","volume":"98","author":"Palomba","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0500","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0301-2115(01)00588-7","article-title":"Effect of different doses of progestin on uterine leiomyomas in postmenopausal women","volume":"102","author":"Palomba","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0505","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5122(00)00115-8","article-title":"Effects of hormone replacement therapy on postmenopausal uterine myoma","volume":"35","author":"Colacurci","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0510","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1471-0528.2000.tb13227.x","article-title":"The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy","volume":"107","author":"Wahab","year":"2000","journal-title":"BJOG"},{"key":"10.1016\/j.jgyn.2011.09.022_bib0515","first-page":"630","article-title":"Measured menstrual blood loss in women with menorrhagia associated with pelvic disease or coagulation disorder","volume":"68","author":"Fraser","year":"1986","journal-title":"Obstet Gynecol"}],"container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231511002596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231511002596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:41:29Z","timestamp":1686444089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0368231511002596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0368231511002596"],"URL":"https:\/\/doi.org\/10.1016\/j.jgyn.2011.09.022","relation":{},"ISSN":["0368-2315"],"issn-type":[{"value":"0368-2315","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}